Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Hannah L. Tumbrink"'
Autor:
Diana Schaufler, David F. Ast, Hannah L. Tumbrink, Nima Abedpour, Lukas Maas, Ayla E. Schwäbe, Inga Spille, Stefanie Lennartz, Jana Fassunke, Mihaela Aldea, Benjamin Besse, David Planchard, Lucia Nogova, Sebastian Michels, Carsten Kobe, Thorsten Persigehl, Theresa Westphal, Sophia Koleczko, Rieke Fischer, Jan-Phillip Weber, Janine Altmüller, Roman K. Thomas, Sabine Merkelbach-Bruse, Oliver Gautschi, Laura Mezquita, Reinhard Büttner, Jürgen Wolf, Martin Peifer, Johannes Brägelmann, Matthias Scheffler, Martin L. Sos
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
Abstract Activation of MAPK signaling via BRAF mutations may limit the activity of EGFR inhibitors in EGFR-mutant lung cancer patients. However, the impact of BRAF mutations on the selection and fitness of emerging resistant clones during anti-EGFR t
Externí odkaz:
https://doaj.org/article/2fe94ce5763c49248add719a2c82fe60
Autor:
Christina M. Bebber, Emily S. Thomas, Jenny Stroh, Zhiyi Chen, Ariadne Androulidaki, Anna Schmitt, Michaela N. Höhne, Lukas Stüker, Cleidson de Pádua Alves, Armin Khonsari, Marcel A. Dammert, Fatma Parmaksiz, Hannah L. Tumbrink, Filippo Beleggia, Martin L. Sos, Jan Riemer, Julie George, Susanne Brodesser, Roman K. Thomas, H. Christian Reinhardt, Silvia von Karstedt
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-19 (2021)
The high degree of subtype plasticity in small cell lung cancer (SCLC) poses a therapeutic challenge. Here, the authors show that the non-neuroendocrine (non-NE) subtype of SCLC is sensitive to ferroptosis while the neuroendocrine (NE) subtype is vul
Externí odkaz:
https://doaj.org/article/72d102a3804747f8993f740dde35ff92
Autor:
Marcel A. Dammert, Johannes Brägelmann, Rachelle R. Olsen, Stefanie Böhm, Niloufar Monhasery, Christopher P. Whitney, Milind D. Chalishazar, Hannah L. Tumbrink, Matthew R. Guthrie, Sebastian Klein, Abbie S. Ireland, Jeremy Ryan, Anna Schmitt, Annika Marx, Luka Ozretić, Roberta Castiglione, Carina Lorenz, Ron D. Jachimowicz, Elmar Wolf, Roman K. Thomas, John T. Poirier, Reinhard Büttner, Triparna Sen, Lauren A. Byers, H. Christian Reinhardt, Anthony Letai, Trudy G. Oliver, Martin L. Sos
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
The expression of oncogenic MYC paralogs in small cell lung cancer is mutually exclusive. In this study, the authors show that MYC, but not MYCN or MYCL, represses BCL2, resulting in cells that are uniquely sensitive to apoptosis, and find that CHK1
Externí odkaz:
https://doaj.org/article/05063d53c99b4d6497e917f9551d71f7
Autor:
Jana Fassunke, Fabienne Müller, Marina Keul, Sebastian Michels, Marcel A. Dammert, Anna Schmitt, Dennis Plenker, Jonas Lategahn, Carina Heydt, Johannes Brägelmann, Hannah L. Tumbrink, Yannic Alber, Sebastian Klein, Alena Heimsoeth, Ilona Dahmen, Rieke N. Fischer, Matthias Scheffler, Michaela A. Ihle, Vanessa Priesner, Andreas H. Scheel, Svenja Wagener, Anna Kron, Konrad Frank, Katia Garbert, Thorsten Persigehl, Michael Püsken, Stefan Haneder, Bernhard Schaaf, Ernst Rodermann, Walburga Engel-Riedel, Enriqueta Felip, Egbert F. Smit, Sabine Merkelbach-Bruse, H. Christian Reinhardt, Stefan M. Kast, Jürgen Wolf, Daniel Rauh, Reinhard Büttner, Martin L. Sos
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Acquired resistance to targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. Here, the authors show how the acquired EGFR G724S mutation induces resistance to third-generation EGFR inhibitors and why the mutant kinase rem
Externí odkaz:
https://doaj.org/article/d0509a8e9f1241e6a692b9bd9e5d0a9b
Autor:
Roman K. Thomas, H. Christian Reinhardt, Martin L. Sos, Martin Peifer, Alison M. Schram, F. Thomas Wunderlich, Kevan M. Shokat, Thorsten Persigehl, Reinhard Büttner, Anna Schmitt, Sebastian Klein, Hannah L. Tumbrink, Johannes Brägelmann, Carina Lorenz, Marcel A. Dammert, Dennis Plenker, Lisa Werr
Supplementary Figure from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::006bacef01864bbdf70bcd37747e88ea
https://doi.org/10.1158/1535-7163.22522992.v1
https://doi.org/10.1158/1535-7163.22522992.v1
Autor:
Roman K. Thomas, H. Christian Reinhardt, Martin L. Sos, Martin Peifer, Alison M. Schram, F. Thomas Wunderlich, Kevan M. Shokat, Thorsten Persigehl, Reinhard Büttner, Anna Schmitt, Sebastian Klein, Hannah L. Tumbrink, Johannes Brägelmann, Carina Lorenz, Marcel A. Dammert, Dennis Plenker, Lisa Werr
NRG1 fusions are recurrent somatic genome alterations occurring across several tumor types, including invasive mucinous lung adenocarcinomas and pancreatic ductal adenocarcinomas and are potentially actionable genetic alterations in these cancers. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb5b84d85a40ab02fd23cb6c8c99405
https://doi.org/10.1158/1535-7163.c.6543543.v1
https://doi.org/10.1158/1535-7163.c.6543543.v1
Autor:
Jonas Lategahn, Hannah L. Tumbrink, Carsten Schultz-Fademrecht, Alena Heimsoeth, Lisa Werr, Janina Niggenaber, Marina Keul, Fatma Parmaksiz, Matthias Baumann, Sascha Menninger, Eldar Zent, Ina Landel, Jörn Weisner, Kirujan Jeyakumar, Leonie Heyden, Nicole Russ, Fabienne Müller, Carina Lorenz, Johannes Brägelmann, Inga Spille, Tobias Grabe, Matthias P. Müller, Johannes M. Heuckmann, Bert M. Klebl, Peter Nussbaumer, Martin L. Sos, Daniel Rauh
Publikováno v:
Journal of Medicinal Chemistry. 65:6643-6655
Despite the clinical efficacy of epidermal growth factor receptor (EGFR) inhibitors, a subset of patients with non-small cell lung cancer displays insertion mutations in exon20 in EGFR and Her2 with limited treatment options. Here, we present the dev
Autor:
Richard Riedel, Jana Fassunke, Hannah L. Tumbrink, Andreas H. Scheel, Carina Heydt, Lena Hieggelke, Matthias Scheffler, Alena Heimsoeth, Lucia Nogova, Sebastian Michels, Jan-Phillip Weber, Rieke N. Fischer, Anna Eisert, Theresa Westphal, Diana Schaufler, Janna Siemanowski, Michaela A. Ihle, Svenja Wagener-Ryczek, Roberta Castiglione, Roberto Pappesch, Jan Rehker, Jessica Jürgens, Erich Stoelben, Anne Bunck, Carsten Kobe, Sabine Merkelbach-Bruse, Martin L. Sos, Reinhard Büttner, Jürgen Wolf
Publikováno v:
European journal of cancer (Oxford, England : 1990). 179
Resistance to MET inhibition occurs inevitably in MET-dependent non-small cell lung cancer and the underlying mechanisms are insufficiently understood. We describe resistance mechanisms in patients with MET exon 14 skipping mutation (METΔPre- and po
Publikováno v:
Oncogene. 40:1-11
EGFR mutations account for the majority of druggable targets in lung adenocarcinoma. Over the past decades the optimization of EGFR inhibitors revolutionized the treatment options for patients suffering from this disease. The pace of this development
Autor:
Philip Klövekorn, Jonas Lategahn, Willem A. L. van Otterlo, Julia Hardick, Tobias Grabe, Daniel Rauh, Luke Hodson, Matthias P. Müller, Tonia Kirschner, Kirujan Jeyakumar, Matthias Baumann, Julia Ketzer, Sebastian Bauer, Susanne Terheyden, Janina Niggenaber, Christian Becker, Anke Unger, Hannah L. Tumbrink, Jörn Weisner, Marina Keul
Publikováno v:
Journal of Medicinal Chemistry. 63:11725-11755
Mutated or amplified Her2 serves as a driver of non-small cell lung cancer or mediates resistance toward the inhibition of its family member epidermal growth factor receptor with small-molecule inhibitors. To date, small-molecule inhibitors targeting